Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
07:10am, Friday, 08'th Nov 2024
All signs are pointing toward its continued success.
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
10:15am, Thursday, 07'th Nov 2024
The company's latest presentation supports the idea that its lead program will make billions.
ATTENTION Viking Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
01:00pm, Wednesday, 06'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) conce
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
12:00pm, Tuesday, 05'th Nov 2024
NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors
Is Viking Therepautics a Buy Now?
04:23am, Tuesday, 05'th Nov 2024
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.
Why Viking Therapeutics Stock Plummeted After Soaring Today
06:33pm, Monday, 04'th Nov 2024
Are we ready for the Great Obesity Drug Gold Rush of the 2020s?
Viking Therapeutics soars then drops on obesity data
06:31pm, Monday, 04'th Nov 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector.
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results
01:05pm, Monday, 04'th Nov 2024
Viking Therapeutics (VKTX) shares fell Monday, handing back early gains, as analysts questioned the path ahead for its developmental weight-loss drugs even after news of upbeat results in clinical tri
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
11:20am, Monday, 04'th Nov 2024
Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
11:07am, Monday, 04'th Nov 2024
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking Therapeutics reports encouraging results from weightloss tablet
10:58am, Monday, 04'th Nov 2024
Viking Therapeutics (NASDAQ:VKTX) shares jumped then fell after it reported results from a trial of its weightloss tablet. The San Diego company said its phase-one clinical trial of an oral table
Biotech Stock Reverses Gains Despite Obesity Pill Buzz
10:42am, Monday, 04'th Nov 2024
Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 4.3% to trade at $74.13 at last glance, reversing course from earlier gains.
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
08:22am, Monday, 04'th Nov 2024
Viking Therapeutics Inc VKTX announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024.
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
07:24am, Monday, 04'th Nov 2024
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations.
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
06:30am, Monday, 04'th Nov 2024
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Re
